Australia Approves Psilocybin And MDMA For Therapeutic Use
Forbes, June 30, 2023
“Australia is creating an interesting model that could pave the way forward for the rest of the world,” Dr. Michael Alpert, a psychiatrist at Harvard Medical School, told ABC News.
Meet the Psychedelic Boom’s First Responders
WIRED, June 29, 2023
A new movement of volunteers will guide you through your psychedelic experience.
Psychedelic-assisted therapies is now legal in Australia
BODY+SOUL, June 29, 2023
The use of psychedelics for the treatment of mental health conditions has been legalised in Australia, but how will it work exactly? Psychedelics are set to be the future of mental health treatments, and this week, they’ll be legally available for use in psychotherapy. As of July 1, psilocybin and MDMA will be available for medicinal use in Australia, making us the first country in the world to do so.
Qld allows use of MDMA, psilocybin to treat mental illness
Courier Mail, June 16, 2023
Queensland mental health patients will have access to psychedelic medicines within weeks after the government quietly changed regulations. Read the full PDF article here.
The Psychedelic Scientist Who Sends Brains Back to Childhood
Wired, June 15, 2023
Kids soak up new skills, adults not so much. But neuroscientist Gül Dölen might have found a way—with medicine—to help grownups learn like little ones.
Aussie psychedelics stocks aim to carve slice out of global market ‘worth $63 billion’
The Daily Telegraph, April 28, 2023
Australia’s psychedelics market could be worth $2 billion, a business leader claims, as five ASX stocks prepare for seismic changes in the industry.
The big idea: should doctors be able to prescribe psychedelics?
The Guardian, April 10, 2023
A move to allow Australian psychiatrists to treat depression with psilocybin may herald a new era
MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation, April 6, 2023
MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced positive topline results from an observational follow-up study evaluating the long-term safety and efficacy of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”). Preliminary findings show that participants in this study demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the Phase 3 study.
Psychedelics Could Revolutionize Couples Therapy
Time, March 14, 2023
“MDMA can build trust, release tension and fear, and erode inhibitions, allowing partners to have hard conversations with compassion and without judgment, says Catherine Auman, a California psychotherapist who coaches clients on how to integrate psychedelics into their lives.”
This psychoactive plant could save lives—and everyone wants to cash in
National Geographic, March 8, 2023
Iboga plants smuggled out of Gabon provide most of the world’s ibogaine, a drug that can help heal trauma and addiction. As the plant enters fair trade, officials hope regulation ensures equity and sustainability.
Australia will allow prescription MDMA and magic mushrooms for some people with mental illness
ABC News USA, March 5, 2023
Australian regulators announced in February that psychiatrists will be able to prescribe psilocybin and MDMA as medication for certain mental health conditions starting July 1 of this year. The move makes Australia the first nation to approve the legal use of MDMA and psilocybin.
Australia is about to legalise MDMA and psilocybin for medicinal use. So how will it work?
ABC News, March 3, 2023
Just three months out from the legalisation of psychedelic medicines for mental health treatment, questions remain among experts about exactly how the drugs will be administered.
Does the ‘hype’ on psychedelics match the reality when it comes to mental health?
News.com.au, February 27, 2023
It sounds crazy doesn’t it? Psychedelic drugs to treat a variety of debilitating mental illness.
But could they be the latest answer to Australia’s spiralling mental health crisis?
The Promise and Perils of Psychedelics
The New England Journal of Medicine, February 23, 2023
In this episode of “Intention to Treat,” a study participant and a long-time investigator of hallucinogenic drugs for psychiatric conditions illuminate the effects of psilocybin in patients with depression.
The Veterans Fighting to Legalize Psychedelics
The New York Times, February 22, 2023
In a major shift that would modify laws set half a decade ago, states and cities around the United States are moving to legalize psychedelics for use as a medical treatment.
The sudden change of heart has a lot to do with who is asking for the substances.
MEPs urge European regulators to move faster on psychedelics
Psychedelic Health, February 21, 2023
Australia’s recent rescheduling of psilocybin and MDMA is inspiring action across the globe.
A group of Members of the European Parliament have sent two letters calling on regulators to move faster on psychedelic healthcare in Europe, stating that “stagnation is creating a disadvantage for millions of Europeans affected by mental health conditions and substance use disorders”.
Psychedelics might change mental healthcare. Will investors follow?
CNBC International, February 17, 2023
Global sales of antidepressant drugs are expected to exceed $20 billion by 2030. Now, some investors are betting that psychedelic therapies can grab a share of that enormous market.
Is it finally time to change the law around magic mushrooms?
Evening Standard, February 16, 2023
Anew digital billboard campaign has appeared around London in the past few days, asking one striking question: Could magic mushrooms be medicine?
Everyone seems to be on psychedelics except me
The Telegraph, January 29, 2023
Read the full PDF here.
Australia’s biggest research trial using psychedelics to treat depression to commence in 2023
Swinburne University, January 25, 2023
Swinburne has signed a $5 million clinical trial research agreement with Woke Pharmaceuticals to embark on Australia’s biggest research trial examining the promise of the active ingredient in psychedelic mushrooms, called ‘psilocybin’, in tackling treatment-resistant depression.